NEW YORK (360Dx) – Fujirebio today announced a deal with Janssen Pharmaceutical to develop and commercialize a test for use with the drug maker's investigational oral BACE inhibitor, atabecestat, for Alzheimer's disease.
The amyloid β 42/40 ratio assay is being developed to identify patients who may benefit from treatment with atabecestat, and will run on the fully automated Lumipulse instrument, a chemiluminescent enzyme immunoassay system. The drug is currently being evaluated for its ability to slow cognitive decline in patients who have been identified by biomarkers to be progressing to Alzheimer's dementia, said Fujirebio, a subsidiary of Miraca Holdings.
The company's portfolio of tests for managing Alzheimer's include the ELISA-based Innotest assay, and its fully automated β-amyloid 1-42 and total TAU assays for the Lumipulse system.
Financial and other terms of the deal were not disclosed.